Giuggioli Dilia, Magistro Rocco, Colaci Michele, Franciosi Umberto, Caruso Andrea, Ferri Clodoveo
Cattedra e UO di Reumatologia, Università di Modena e Reggio Emilia, Italia.
Reumatismo. 2006 Jan-Mar;58(1):26-30. doi: 10.4081/reumatismo.2006.26.
To verify the effectiveness of G-CSF in the treatment of non-healing skin lesions in SSc patients.
26 SSc patients (23 F and 3 M, age 54 +/-13,6 yrs) with skin ulcers were enrolled in a pilot study. Prior to the treatment with G-CSF, all ulcers failed to heal with conventional therapies carried out for a period of 1-5 years. All patients were treated with 5 microg/kg G-CSF subcutaneously for 5 days. Healing time, quality of wounds, VAS and HAQ-DI were used to evaluate the efficacy of the treatment.
An improvement of skin ulcers was observed in 24/26 patients; in particular, 22/26 wounds completely healed, 2/26 showed a partial healing, in only 2 patients skin ulcers did not change during the 6-month follow-up. The quality of life improves as showed by VAS (from 88+/-13 to 55+/-28; p<.0001) and HAQ (from 2.12 +/-0.45 to 1.28+/-0.30; p<.0001). The eradication of pathogens from the infected ulcers was also observed in 12/12 patients; while no adverse side effects related to G-CSF were recorded. Our study suggests that G-CSF may be usefully employed in scleroderma skin ulcers refractory to conventional treatments.
验证粒细胞集落刺激因子（G-CSF）治疗系统性硬化症（SSc）患者不愈合皮肤损伤的有效性。
26例患有皮肤溃疡的SSc患者（23例女性，3例男性，年龄54±13.6岁）纳入一项初步研究。在使用G-CSF治疗前，所有溃疡在进行1至5年的传统治疗后均未愈合。所有患者皮下注射5μg/kg G-CSF，共5天。采用愈合时间、伤口质量、视觉模拟评分（VAS）和健康评估问卷残疾指数（HAQ-DI）评估治疗效果。
24/26例患者的皮肤溃疡有所改善；具体而言，22/26处伤口完全愈合，2/26处部分愈合，仅2例患者的皮肤溃疡在6个月随访期间未发生变化。VAS（从88±13降至55±28；p<0.0001）和HAQ（从2.12±0.45降至1.28±0.30；p<0.0001）显示生活质量有所改善。12/12例患者的感染性溃疡中也观察到病原体清除；未记录到与G-CSF相关的不良副作用。我们的研究表明，G-CSF可能有效地用于传统治疗难治的硬皮病皮肤溃疡。
